|Dr. Ramesh Kumar Ph.D.||Co-Founder, Chief Exec. Officer, Pres & Director||686.91k||N/A||61|
|Dr. E. Premkumar Reddy Ph.D.||Founder, Lead Scientific Advisor & Director||161k||N/A||73|
|Dr. Manoj Maniar Ph.D.||Sr. VP of Product Devel.||509.57k||N/A||54|
|Dr. Steven M. Fruchtman M.D.||Chief Medical Officer & Sr. VP of R&D||571.76k||N/A||66|
|Mr. Mark Patrick Guerin||Chief Financial Officer||N/A||N/A||48|
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. The companys clinical-stage product candidates include Rigosertib IV, which is in Phase III clinical trials for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trials for patients with MDS and acute myelogenous leukemia; and Rigosertib oral, which is in Phase II clinical trials for patients with lower risk MDS. Its clinical-stage product candidates also comprise Briciclib, which is in Phase I multisite dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. In addition, the company has various product candidates in preclinical development that target kinases, cellular metabolism, or cell division. It has a development and license agreement with Baxter Healthcare SA; and a license agreement with SymBio Pharmaceuticals Limited. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.
Onconova Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.